Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7167520 | 0.82 | TSHR (0.52) | CES2TSHRMAPK1MGLLMAPT | |
| SCHEMBL2153943 | 0.78 | HDAC8 (0.47) | ALDH1A1P2RX1RAB9A | |
| SCHEMBL10705760 | 0.78 | TSHR (0.48) | CES2TSHRMAPK1MGLLMAPT | |
| SCHEMBL3025058 | 0.78 | CES2 (0.48) | CES2TSHRMAPK1MGLLMAPT | |
| SCHEMBL7798387 | 0.77 | CES2 (0.46) | CES2TSHRMAPTALDH1A1P2RX1 | |
| SCHEMBL29149633 | 0.76 | TSHR (0.52) | TSHRMAPK1MAPTALDH1A1LMNA | |
| SCHEMBL62723 | 0.75 | TSHR (0.67) | CES2TSHRMAPK1MGLLMAPT | |
| SCHEMBL2154620 | 0.74 | HDAC8 (0.43) | MAPK1MAPTALDH1A1KMT2AHTT | |
| Benzene SCHEMBL8568955 | 0.73 | TSHR (0.67) | CES2TSHRMAPK1MGLLMAPT | |
| SCHEMBL30553105 | 0.73 | TSHR (0.64) | CES2TSHRMAPK1MGLLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722912-B2 | Metal complex compound and process for producing amides utilizing the metal complex compound | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2014-05-13 | — | — | US | disclosed |
| US-20130131366-A1 | Metal Complex Compound and Process for Producing Amides Utilizing the Metal Complex Compound | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2013-05-23 | — | — | US | disclosed |
| EP-0731105-B1 | Optically active tertiary phosphine compounds, transition metal complexes comprising the same as ligands and process for preparing optically active organic silicon compounds using said transition metal complexes | SUMITOMO CHEMICAL CO (JP) | 2001-12-05 | — | — | EP | disclosed |
| US-5621129-A | Optically active tertiary phosphine compound, transition metal complex comprising the same as ligand and process for preparing optically active organic silicon compound using said transition metal complex | SUMITOMO CHEMICAL CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0731105-A1 | Optically active tertiary phosphine compounds, transition metal complexes comprising the same as ligands and process for preparing optically active organic silicon compounds using said transition metal complexes | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131366-A1 | Metal Complex Compound and Process for Producing Amides Utilizing the Metal Complex Compound | AP2M1, ASH2L, AP2A1 | CES2 3764/4885TSHR 1738/4885MAPK1 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.